I'm LongbridgeAI, I can summarize articles.Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has issued an announcement.
Three new indications for Hansoh’s innovative medicines were added to the 2026 National Reimbursement Drug List: Ameile with pemetrexed and platinum-based chemotherapy as first-line treatment for eligible adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, and XINYUE for adult IgG4-related disease and antibody-positive adult generalized myasthenia gravis.
The renewal also covers four remaining Ameile indications, one remaining XINYUE indication, Hansoh Xinfu and Fulaimei, with Fulaimei’s medical-insurance payment scope expanded. Saint Luolai and Hengmu remain within NRDL agreements, while Mailingda is included in category B; Hansoh stated that all approved indications of its marketed innovative medicines are included, helping improve patients’ affordability and access.